Expression and Association of Tumor Necrosis Factor Receptor Associated Factor 4 (TRAF4) in Esophageal Squamous Cell Carcinoma

Background: At present, there is no effective targeted therapy for esophageal squamous cell carcinoma (ESCC), and it is urgent to find new targets for the treatment of ESCC. TRAF4 has been regarded as a cause of carcinogenesis due to overexpression in many cancer types and participation in multiple signaling pathways. However, there are few studies on TRAF4 in ESCC worldwide. Its expression in ESCC and whether it affects the prognosis of patients still remain unclear.

Material/Methods: We detected the expressions of TRAF4, ki-67, and p53 in 100 cases of ESCC and 80 cases of adjacent normal esophageal squamous epithelium tissues by immunohistochemical technique. We further explored the relationship between TRAF4 and ESCC and its prognosis through statistical analysis.

Results: TRAF4 was highly expressed in ESCC tissues and was mainly expressed in the cytoplasm. Overexpression of TRAF4 in ESCC was also associated with high expression of ki-67 and p53 (P<0.05). We also found that patients with high expression of TRAF4 had significantly lower OS than in patients with low TRAF4 expression (P<0.05). Overexpression of TRAF4 was an independent risk factor affecting the prognosis of patients (P<0.05).

Conclusions: We found that TRAF4 was highly expressed in ESCC tissues and was mainly expressed in the cytoplasm of cancer cells. Overexpression of TRAF4 was an independent risk factor affecting the overall prognosis of patients. The results indicated that TRAF4 may become a new target for the treatment of ESCC in the future.

MeSH Keywords: Esophageal Neoplasms • Ki-67 Antigen • Prognosis • TNF Receptor-Associated Factor 4 • Tumor Suppressor Protein p53

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/915474
Background

According to epidemiological statistics, China is a high-incidence area of esophageal squamous cell carcinoma, which is more common in men over 40 years old. Treatment of esophageal cancer is mainly early surgical treatment, but many patients diagnosed at later stages have high morbidity and mortality rates and have lost the opportunity for early surgery, and there is still no effective targeted therapy [1]. Esophageal cancer is more common in people with adenocarcinoma in Europe and the Americas. Most studies on esophageal cancer are mainly based on adenocarcinoma. It is urgent to find new targets for the treatment of esophageal squamous cell carcinoma.

Tumor necrosis factor receptor-related factor (TRAF) is an important intracellular signaling proteins of tumor necrosis factor receptor (TNFR), which activates the transcription factor NF-κB and JNK pathway by adjusting a variety of signal transduction pathways, such as the IL-1/Toll-like receptors, so as to regulate cell proliferation, differentiation, apoptosis, immune and inflammatory reaction and so on [2–4]. In 1994, Rothe et al. first discovered 2 proteins specific to TNFR binding in mouse cytotoxic T cell lines and named them TNFR1 and TNFR2. So far, 7 different TRAFs have been found [5]. These molecules share some structural properties. It mediates the interaction of TRAFs molecules, receptors, and corresponding signal proteins in cells through the homologous domain of its own carboxyl radicals. The signal is transmitted downstream through the interaction between DNA and protein through the ring finger/zinc finger domain contained in the amino terminal [6]. Among many family molecules, TRAF4 is the only one found in the nucleus, which may be related to some primary tumors and metastases. However, whether TRAF4 is mainly expressed in the nucleus or cytoplasm in tumor tissues has been controversial [7]. Unlike other family members that regulate immune and inflammatory responses, TRAF4 has been shown to be involved in the development and progression of multiple tumors [8,9]. TRAF4 is also expressed during embryonic development and is a key molecule in the process of individual development [10]. In recent years, studies around the world have found that TRAF4 is often highly expressed in breast cancer, lung cancer, colorectal cancer, and other tumors, and also affects the survival and prognosis of patients [11].

We predicted the expression of TRAF4 gene in esophageal cancer in advance through bioinformatics analysis. Our results suggest that the expression of TRAF4 in esophageal cancer and normal tissues may be different (Figure 1A, 1B). Therefore, we used immunohistochemistry to detect the distribution and expression of TRAF4 in esophageal squamous cell carcinoma and adjacent tissues, and performed statistical analysis of the correlation between OS and clinical features. To investigate the expression and association of TRAF4 in esophageal squamous cell carcinoma, we also studied the relationship between TRAF4, ki-67, and p53 expression.

Material and Methods

Patients and specimens

We collected 100 tissue samples of esophageal cancer patients from Anhui Provincial Hospital from January 2008 to December 2012, and made tissue chips. Specimens were obtained from 74 male and 26 female patients, ages 48–82 years (mean age 65.3 years), all based on pathological confirmation of a clear diagnosis of ESCC. None of the patients had received radiotherapy, chemotherapy, or immunotherapy. These tissues were from patients undergoing esophagectomy. Among them, 80 patients had corresponding specimens of cancer and adjacent normal esophageal squamous epithelium tissues, numbered 1–80. The remaining 20 cases had only esophageal cancer specimens, numbered 80–100. The clinicopathological data on sex, age, tumor size, lymphatic metastasis, and TNM stage of all patients were collected from the case management system of the medical records room of Anhui Provincial Hospital. Follow-up lasted until July 2017. The study was approved by the Anhui Provincial Hospital Ethics Committee and all patients signed a written informed consent form.

Tissue chip manufacturing steps

The pathological tissue wax block was selected from the Pathology Department, and the conventional pathological section was followed by HE staining. We invited the pathologist to locate the tumor tissue in the wax block. We used a US Beecher array instrument to make a hole (2 mm in diameter) on the blank wax block, and then accurately removed the desired tissue at the corresponding position of the tissue wax block according to the precise range drawn on the HE-stained section. After that, we put the desired tissue in the hole of the blank wax block, the number of the tissue placed in each hole was recorded in detail, and the above operation was repeated. Each specimen was taken from a single piece of cancer and adjacent tissues (3–5 cm from the cancer tissue) to make an array block. We used a microtome to slice continuously. After that, routine HE staining was performed, and 2 pathologists checked whether each of the chips was consistent with the design. Then, we assessed the qualified slice lines by immunohistochemistry.

Immunohistochemistry

The levels of TRAF4 were assessed by immunohistochemistry. Mouse anti-human TRAF4 monoclonal antibody was purchased from Santa Cruz (USA) diluted 1: 100.
The immunohistochemistry kit and DAB chromogenic reagent are all products of Zymed Co. (USA). Immunohistochemical staining was carried out according to the instructions of the SP kit. The tissue chips were oven-dried overnight at 70°C. After routine dewaxing and hydration, 3% hydrogen peroxide was used to block endogenous peroxidase for 15 min. After rinsing with PBS, we then put it in citrate buffer, performed antigen retrieval by microwave or high pressure for 15 min, cooled it at room temperature, and treated it with normal goat blocking serum for 15 min at room temperature, and then an antibody was added at room temperature for 2 h at 4°C overnight. Then, we added biotin-labeled secondary antibody, incubate it for 15 min at room temperature, stained it with DAB, rinse it thoroughly with water, and stopped the reaction with hematoxylin. Positive and negative controls were set during the staining process, and the negative control was replaced with PBC instead of the primary antibody. The same immunohistochemical method was used to detect the expression of ki-67 and p53 in cancer and adjacent tissues.

**Determination of immunohistochemical results**

We used positive range and intensity to analyze TRAF4 expression. The staining intensity scores were as follows: 0 (negative staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown), 3 (strong staining, brown). We used positive staining cells as a percentage of field of view to assess positive staining range: 0 (negative), 1 (positive rate <25%), 2 (positive rate 26–50%), 3 (positive rate 51–75%), and 4 (positive rate 75–100%). The final score was determined by multiplying the intensity score and the positive range. By observing at least 5 high-power fields and scores, a total score >4 was considered high expression. Ki-67 and p53 expression was quantified by using a visual grading system [12]. In this experiment, the p53 and ki-67 positive criteria were judged as: 0 (negative staining), 1 (<10% positive for diseased cells), 2 (10–50% positive for diseased cells), and 3 (>50% positive for diseased cells); 0 and 1 points are negative, and 2 and 3 points are positive [13]. All results were evaluated by 2 pathologists who were blinded to the experiment.

**Statistical analysis**

Statistical analyses were performed with SPSS version 22.0 software (IBM, Armonk, NY). Differences between groups were compared using the \( \chi^2 \) test. The relationship between TRAF4 expression and clinicopathologic characteristics and prognosis were explored by Kaplan-Meier survival analysis and log-rank test. Correlation analysis between the 2 variables was performed by using Spearman’s rank correlation analysis, and among multiple factors using Cox regression. \( P < 0.05 \) was considered to indicate a statistically significant difference.

**Results**

**Expression and localization of TRAF4 in esophageal cancer and adjacent tissues**

After immunohistochemical staining of the tissue microarray, we obtained 80 pairs of cancer tissues and corresponding adjacent normal esophageal squamous epithelium tissues, as well as 20 separate esophageal cancer tissues. During the operation, there were no squamous epithelium in 5 adjacent tissues. The results showed that although TARF4 is expressed in the nucleus and cytoplasm of esophageal cancer cells at the same time, but it is mainly expressed in the cytoplasm (85% vs. 44%). The expression of TRAF4 in the cytoplasm of...
Table 1. (A) Difference of TRAF4 expression level in cytoplasm between esophageal squamous cell carcinoma and adjacent normal tissues. (B) Difference of TRAF4 expression level in nucleus between esophageal squamous cell carcinoma and adjacent normal tissues.

|                  | TRAF4 expression level in cytoplasm | Sum | High rate |
|------------------|-------------------------------------|-----|-----------|
|                  | High | Low |         |
| ESCC tissues     | 85   | 15  | 100      | 85%     |
| Adjacent normal tissues | 16   | 59  | 75       | 21%     |

|                  | TRAF4 expression level in nucleus | Sum | High rate |
|------------------|----------------------------------|-----|-----------|
|                  | High | Low |         |
| ESCC tissues     | 44   | 56  | 100      | 44%     |
| Adjacent normal tissues | 6    | 69  | 75       | 8%      |

Figure 2. Immunohistochemical staining of esophageal cancer and adjacent tissues at 200× magnification. (A) TRAF4 was overexpressed in the cytoplasm of esophageal cancer cells. (B) TRAF4 is under-expressed in the adjacent normal tissues.

esophageal cancer cells was significantly higher than in adjacent normal tissues (85/100 vs. 16/75, $\chi^2=71.2$, $P<0.01$ Table 1A, Figure 2A, 2B). In addition, the expression of TRAF4 in the nucleus of esophageal cancer cells was significantly higher than in adjacent normal tissues (44/100 vs. 6/75, $\chi^2=27.2$, $P<0.01$, Table 1B). The results show that TRAF4 is highly expressed in ESCC, and is mainly expressed in cytoplasm.
Relationship between high expression of TRAF4 in cytoplasm of esophageal carcinoma and expression of ki-67 and p53

To explore the relationship between the expression of TRAF4 and ki-67 and P53 in esophageal cancer tissues, we serially sliced the tissue chip to obtain high-quality serial sections for immunohistochemistry under the same conditions. Immunohistochemical staining results showed that TRAF4 was highly expressed in ESCC tissues, and ki-67 and p53 were highly expressed in serial sections of the same site (Figure 3A–3D). We performed Spearman correlation analysis, and the results showed that high expression of TRAF4 in esophageal cancer tissues is often accompanied by high expression of ki-67 (r=0.512, P<0.01, Figure 3C) and P53 (r=0.234, P<0.05, Figure 3D). Our bioinformatics prediction by using the GEPIA website (TCGA data) also supports our results (Figure 4A, 4B).

We further explored the relationship between the expression of TRAF4, ki-67, and p53 and clinicopathological features in esophageal cancer tissues. High expression of TRAF4 in ESCC tissues is associated with sex (P=0.048). The high expression of ki-67 in esophageal cancer tissues is usually accompanied by lymphatic metastasis and higher TNM staging. High expression of p53 was also positively correlated with TNM staging. However, we did not find a relationship between the expression of TRAF4 in ESCC tissues and age, tumor size, lymph node metastasis, TNM stage, or pathological stage (Table 2).

Relationship between expression of TRAF4 in esophageal cancer tissues and patient prognosis

We found that the overall survival (OS) of patients with high expression of TRAF4 was significantly lower than that of patients with low expression of TRAF4 by Kaplan-Meier survival analysis and log-rank statistical test (95%CI 23.337–37.763 vs. 44.409–78.546, P<0.01, Figure 5A). Patient sex, tumor size, lymph node metastasis, and TNM staging were also associated with OS (P<0.05, Figure 5B–5E). However, there was no association between patient pathological staging and patient OS (P>0.05, Figure 5F). Our further Cox multivariate analysis suggested that overexpression of TRAF4 was closely associated with patient prognosis, and it was an independent risk factor for OS in patients with esophageal squamous cell carcinoma (Table 3).

Discussion

Since it was first discovered in human breast cancer tissues in 1995, TRAF4 has been regarded as an oncogene due to overexpression in many cancer types and is thought to be involved...
in carcinogenesis by participating in multiple signaling pathways. Camilleri et al. performed immunohistochemical analysis of pathological specimens from 623 patients with 20 different tumor types, and found that TRAF4 was overexpressed in various tumor cells such as breast cancer and lung adenocarcinoma, liver cancer, and colon cancer, including lung adenocarcinoma. Overexpression of TRAF4 was observed in 60% of tissues (82 of 137). TRAF4 may play an important role in most tumor proliferation signaling pathways [14]. In China, the prevalent type of esophageal cancer is squamous cell carcinoma [15]. However, there are few studies on TRAF4 overexpression in esophageal squamous cell carcinoma and the relationship with patient prognosis. In the present immunohistochemistry study of 100 patients with esophageal cancer, we found that TRAF4 is mainly localized in the cytoplasm, and only a small amount is expressed in the nucleus. By comparing 80 pairs of cancer tissues with corresponding adjacent tissues, we found that the expression of TRAF4 in esophageal squamous cell carcinoma was associated with p53.

Table 2. The relationship between TRAF4, ki-67 and p53 expression and the clinicopathologic features in 100 ESCC patients(cases).

|               | Sum | TRAF4 | Ki-67 | p53 |
|---------------|-----|-------|-------|------|
|               |     | High  | Low   |      | High | Low  |      |      |
| Gender        |     |       |       |      |      |      |      |      |
| Male          | 74  | 66    | 8     | 3.917| 0.048| 46   | 28   | 0.016|
| Female        | 26  | 19    | 7     | 15   | 0.112| 15   | 11   | 0.003|
| Age           |     |       |       |      |      |      |      |      |
| ≤65           | 51  | 43    | 8     | 0.038| 0.845| 32   | 19   | 0.013|
| >65           | 49  | 42    | 7     | 0.013| 0.715| 29   | 20   | 0.007|
| Tumor size    |     |       |       |      |      |      |      |      |
| ≤5            | 56  | 46    | 10    | 0.005| 0.944| 31   | 25   | 0.353|
| >5            | 29  | 24    | 5     | 0.006| 0.714| 18   | 11   | 0.006|
| Lymphatic     |     |       |       |      |      |      |      |      |
| metastasis    |     |       |       |      |      |      |      |      |
| Yes           | 54  | 49    | 5     | 3.21 | 0.073| 39   | 15   | 0.007|
| No            | 45  | 35    | 10    | 1.65 | 0.125| 22   | 23   | 0.006|
| TNM stages    |     |       |       |      |      |      |      |      |
| I/II          | 46  | 37    | 9     | 0.189| 0.039| 22   | 24   | 0.011|
| III           | 50  | 45    | 5     | 0.019| 0.325| 38   | 11   | 0.005|
| Pathological  |     |       |       |      |      |      |      |      |
| grading       |     |       |       |      |      |      |      |      |
| I/II          | 72  | 61    | 11    | 0.016| 0.901| 40   | 32   | 0.045|
| III           | 28  | 24    | 4     | 0.012| 0.686| 21   | 7    | 0.015|

Figure 4. Retrospective analysis of the database. (A) The expression of TRAF4 in esophageal cancer was associated with p53. (B) The expression of TRAF4 in esophageal cancer was associated with Ki67.

|        | log2 (TRAF4 TPM) | p-value=0.00075 | R=0.25 |
|--------|------------------|------------------|--------|
| 4      | 5                | 6                | 7      |
| 8      | 9                | 10               | 11     |
| log2 (TP53 TPM) p-value=0.00016 R=0.28 | 78 |
| 45    | 6                | 5                | 4      |
| 3    | 2                | 1                | 0      |

Table 2. The relationship between TRAF4, ki-67 and p53 expression and the clinicopathologic features in 100 ESCC patients(cases).
Figure 5. Kaplan-Meier analysis of overall survival (OS) of patients with esophageal squamous cell carcinoma (ESCC). (A) OS curve of patients with ESCC based on TRAF4 expression in tumor tissues; (B) OS curve of patients with ESCC based on sex; (C) OS curve of patients with ESCC based on tumor size; (D) OS curve of patients with ESCC based on lymphatic metastasis; (E) OS curve of patients with ESCC based on TNM stages; (F) OS curve of patients with ESCC based on pathological grading.
Table 3. Univariate and multivariate analysis of factors associated with OS.

| OS                  | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | Estimate            | 95 CI                 | P        | HR      | 95 CI                 | P        |
| TRAF4 expression    | High                | 30.55                 | 23.337–37.763 | 0.004   | 2.789                | 1.221–6.356 | 0.015   |
|                     | Low                 | 61.478                | 44.409–78.546 | 0.006   | 0.485                | 0.232–1.012 | 0.054   |
| Sex                 | Male                | 29.176                | 22.050–43.094 | 0.006   | 0.485                | 0.232–1.012 | 0.054   |
|                     | Female              | 54.594                | 37.973–71.216 | 0.006   | 0.485                | 0.232–1.012 | 0.054   |
| Tumor size (cm)     | ≤ 5                 | 41.924                | 32.521–51.336 | 0.043   | 0.681                | 0.401–1.156 | 0.681   |
|                     | > 5                 | 28.276                | 15.772–40.779 | 0.043   | 0.681                | 0.401–1.156 | 0.681   |
| Lymphatic metastasis| Yes                 | 22.247                | 16.319–28.174 | 0.001   | 4.155                | 0.984–17.543 | 0.053   |
|                     | No                  | 48.306                | 36.494–60.118 | 0.001   | 4.155                | 0.984–17.543 | 0.053   |
| TNM stages          | I/II                | 49.992                | 37.903–62.081 | <0.001  | 0.099                | 0.023–0.417 | 0.002   |
|                     | III                 | 19.000                | 14.111–23.889 | <0.001  | 0.099                | 0.023–0.417 | 0.002   |

In recent years, some scholars have found that changing the expression level of TRAF4 by gene vector can affect the malignant behavior of cancer cells. For example, Jiang used small interfering RNA (siRNA) to silence the expression of TRAF4 gene in esophageal cancer cell Eca-109, and found that the inhibition rate, apoptosis rate, and caspase-3 activation rate of proliferation in the silent group were increased (P<0.05), and the proportion of cells in G0/G1 phase was significantly higher than in the control group (P<0.05) [19]. Yao also found that silencing TRAF4 inhibits osteosarcoma cell growth in vivo and in vitro, consistent with these findings [20]. In addition, some studies have found that downregulation of TRAF4 levels has an effect of inhibiting the progression of non-small cell lung cancer [21]. Coincidentally, Zhang found that the proliferation ability of MDA-MB-231 cells was enhanced by the overexpression of TRAF4 in breast cancer cells, and the proportion of cells in S phase was increased [22]. The above results indicate that targeting silencing of TRAF4 can inhibit the growth of malignant tumors, and the expression of TRAF4 can affect the occurrence and development of tumors.

Through further Kaplan-Meier and log-rank statistical tests, we found that the overall survival (OS) of patients with high expression of TRAF4 in the cytosol was significantly lower than that of patients with low expression of TRAF4, and the Cox multivariate analysis suggests that TRAF4 is an independent risk factor affecting overall patient survival. These results suggest that TRAF4 is involved in the development of esophageal squamous cell carcinoma. The high expression of TRAF4 suggests a poor overall prognosis. Targeted silencing of TRAF4 may benefit patients with advanced esophageal squamous cell carcinoma. In the future, TRAF4 gene knockout and inhibition of TRAF4 expression may promote apoptosis of esophageal cells, and inhibit proliferation and distant metastasis.
We were not able to deeply study the specific mechanism by which TRAF4 affects the prognosis of patients. In the future, we will collect specimens and expand the sample size of the experiment. Further research is needed on the mechanism of TRAF4 in the occurrence and development of ESCC.

References:

1. Siegel RL, Miller KD: Cancer statistics, 2015. Cancer J Clin, 2015; 65: 5–29
2. Wan-qiao Z et al: [Intracellular adaptor proteins TRAFs family.] Chinese Bulletin of Life Sciences, 2008; 20(4): 611–17 [in Chinese]
3. Ahmed F, Shiraiishi T, Vessella RL: Tumor necrosis factor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep, 2013; 30: 2963–68
4. Esparza EM: TRAF4 functions as an intermediate of GITR-induced NF-κB activation. Cell Mol Life Sci, 2004; 61: 3087–92
5. Rothe M, Wong SC, Henzel WJ: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell, 1994; 78: 681–92
6. Takayanagi H, Ogasawara K, Hida S et al: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 2000; 408: 600–5
7. Glauner H, Siegmund D, Motejadded H et al: Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4). Eur J Biochem, 2002; 269: 4819–29
8. Zhao Z, Ren HY, Yang F et al: Expression, correlation, and prognostic value of TRAF2 and TRAF4 expression in malignant plural effusion cells in human breast cancer. Diagn Cytopathol, 2015; 43: 897–903
9. Ren HY, Wang J, Yang F et al: Cytoplasmic TRAF4 contributes to the activation of p70S6k signaling pathway in breast cancer. Oncotarget, 2015; 6: 4080–96
10. Masson R, Régnier CH, Chenard MP et al: Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development. Mech Dev, 1998; 71: 187–91
11. Haiyang Z, Guowu Q, Xin W et al: [Effect of RNA interference of TRAF4 expression on apoptosis and Wnt signaling pathway in rectal cancer cells.] Journal of Qingdao University, 2018; 54(4): 415–22 [in Chinese]

Conclusions

We found that TRAF4 was highly expressed in ESCC tissues and was mainly expressed in the cytoplasm of cancer cells. The high expression of TRAF4 was also accompanied by high expression of ki-67 and p53. Patients with high expression of TRAF4 had significantly lower OS than patients with low TRAF4 expression. Overexpression of TRAF4 was an independent risk factor affecting the prognosis of patients, indicating that TRAF4 may become a new target for the treatment of ESCC in the future.